Söndag 5 Januari | 07:53:51 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-11-06 13:30 Kvartalsrapport 2025-Q3
2025-08-21 13:30 Kvartalsrapport 2025-Q2
2025-05-08 13:30 Kvartalsrapport 2025-Q1
2025-02-27 08:00 Bokslutskommuniké 2024
2024-12-18 - Extra Bolagsstämma 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-21 - Kvartalsrapport 2024-Q2
2024-05-16 - X-dag ordinarie utdelning STENO 0.00 DKK
2024-05-15 - Årsstämma
2024-05-02 - Kvartalsrapport 2024-Q1
2024-02-22 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-06-20 - Kvartalsrapport 2023-Q1
2023-06-13 - Extra Bolagsstämma 2023
2023-05-22 - X-dag ordinarie utdelning STENO 0.00 DKK
2023-02-23 - Bokslutskommuniké 2022
2022-11-18 - Extra Bolagsstämma 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-20 - X-dag ordinarie utdelning STENO 0.00 DKK
2022-05-19 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-24 - Bokslutskommuniké 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-21 - X-dag ordinarie utdelning STENO 0.00 DKK
2021-05-20 - Årsstämma
2021-05-06 - Kvartalsrapport 2021-Q1
2021-02-25 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-15 - X-dag ordinarie utdelning STENO 0.00 DKK
2020-05-14 - Årsstämma
2020-05-07 - Kvartalsrapport 2020-Q1
2020-02-26 - Bokslutskommuniké 2019
2019-11-06 - Kvartalsrapport 2019-Q3
2019-08-20 - Kvartalsrapport 2019-Q2
2019-05-07 - Kvartalsrapport 2019-Q1
2019-02-21 - Bokslutskommuniké 2018

Beskrivning

LandDanmark
ListaFirst North Denmark
SektorHälsovård
IndustriLäkemedel & Handel
Stenocare är verksamt inom hälsovårdsindustrin. Bolaget är specialiserat inom utveckling av medicinsk cannabis. Stenocare är en av de första aktören att ha påbörjat försäljning av medicinska cannabisoljor i Danmark. Bolaget kommer framöver även vända sig till övriga europeiska marknader med sitt produktutbud. Stenocares huvudkontor ligger i Randers.
2024-12-10 15:38:44

STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK

TICKER:  STENO

Stenocare has announced its STENOCARE 3.0 strategy, unveiled on November 26, which marks a bold new chapter in its mission to become a leader in the medical cannabis industry. This transformative strategy positions Stenocare as a specialised Trading Company, focused on delivering high-quality, prescription-based medical cannabis products to carefully selected markets. By leveraging innovation and global partnerships, Stenocare aims to create superior value for patients and stakeholders.

The management team recently shared their insights into this strategic shift in an interview with ProInvestor.com, now available on the Stenocare Facebook page and the Proinvestor website:

At the heart of the strategy is the revolutionary ASTRUM 10-10 oil product, which has been approved for sale in Australia, Germany, and Norway. This patented product offers a significant competitive edge by improving bioavailability, ensuring greater predictability in dosage delivery for patients. Stenocare holds the exclusive global rights to this breakthrough technology in the medical cannabis space.

In addition to product innovation, Stenocare has established a strong international presence, with valuable assets in 6 countries and 13 products approved for sale by local health authorities. The company's proven logistical and distribution model ensures high-quality products reach patients efficiently across Europe and Australia.

"Our STENOCARE 3.0 strategy is a game-changer," said Thomas Skovlund Schnegelsberg, CEO of Stenocare. "By focusing on innovation and strategic partnerships, we are not only strengthening our competitive position but also enhancing our ability to serve patients with reliable and high-quality medical cannabis products."

With ambitious plans to grow sales and expand market share, Stenocare is poised to lead the way in a rapidly evolving industry.